News & Events

Impel NeuroPharma to Present Data at 2019 American Psychiatric Association (APA) Annual Meeting

SEATTLE, May 17, 2019 — Phase 1 Data Support Selection of Company’s Proprietary Formulation of Investigational Nasal Olanzapine, INP105, Currently Being Evaluated for Acute Agitation in Bipolar 1 and Schizophrenia


Impel NeuroPharma To Present Data Highlighting Late-Stage Central Nervous System Pipeline At 2019 American Academy Of Neurology Meeting

SEATTLE, April 30, 2019 — Safety, Tolerability and Comparative Bioavailability Data Support INP104, Impel’s Nasal Drug Candidate for Acute Migraine Results from the Company’s Phase 3 Clinical Program Evaluating INP104 for the Treatment of Acute Migraine Anticipated in Late 2019…


Impel NeuroPharma Appoints Jennifer L. Berman as Vice President of Marketing

SEATTLE, February 19, 2019 — Significant Leadership Experience in CNS Marketing to Help Impel Evolve into a Fully-Integrated R&D and Commercial Organization. Impel NeuroPharma today announced that Jennifer L. Berman has joined the Company as the Vice President of Marketing.